Celikbilek Asuman, Sabah Seda, Tanik Nermin, Ak Hakan, Atalay Tugay, Yilmaz Neziha
Department of Neurology, Bozok University, Medical School, 66200, Yozgat, Turkey,
Neurol Sci. 2014 Aug;35(8):1197-201. doi: 10.1007/s10072-014-1679-7. Epub 2014 Feb 16.
Experimental data have demonstrated a role for S100B protein through the release of proinflammatory cytokines, following trigeminal nerve activation, implicated in the pathology of migraine. We investigated serum levels of S100B protein, as a peripheral glial biomarker, in patients with migraine. In total, 49 migraineurs and 35 age- and gender-matched controls were enrolled in this prospective clinical study. The migraine diagnosis was made according to the International Classification of Headache Disorders II diagnostic criteria. Serum samples were obtained for the measurement of S100B levels from all participants and were analyzed using commercial enzyme-linked immunosorbent assay kits. Serum S100B levels were significantly lower in migraineurs than controls (p < 0.001). S100B levels did not significantly differ in migraineurs with or without aura (p > 0.05). In addition, there was no correlation between serum S100B levels and headache characteristics, including attack severity, frequency and duration, and disease duration (p > 0.05). These findings suggest that serum S100B levels were significantly decreased in migraine patients, but further research is needed to ascertain the contribution of S100B in the clinical evaluation of migraine.
实验数据表明，三叉神经激活后，S100B蛋白通过释放促炎细胞因子发挥作用，这与偏头痛的病理过程有关。我们研究了偏头痛患者血清中S100B蛋白水平，它是一种外周神经胶质生物标志物。本前瞻性临床研究共纳入49例偏头痛患者和35例年龄及性别匹配的对照者。偏头痛诊断依据《国际头痛疾病分类第二版》诊断标准。采集所有参与者的血清样本用于检测S100B水平，并使用商用酶联免疫吸附测定试剂盒进行分析。偏头痛患者的血清S100B水平显著低于对照组（p < 0.001）。有先兆和无先兆的偏头痛患者的S100B水平无显著差异（p > 0.05）。此外，血清S100B水平与头痛特征（包括发作严重程度、频率和持续时间）以及病程之间无相关性（p > 0.05）。这些发现表明偏头痛患者的血清S100B水平显著降低，但需要进一步研究以确定S100B在偏头痛临床评估中的作用。
